# DT-216 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dt-216

> DT-216, sponsored by Design Therapeutics, Inc. (DSGN): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | DT-216 |
| Codes | DT-216 |
| Sponsor | Design Therapeutics, Inc. (DSGN) https://sec-api.dev/companies/dsgn/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2022: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 1.
- First seen 2025-03-10, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001193125-25-266970): "In December 2022, we reported positive initial data from the Phase 1 single-ascending dose (SAD) clinical trial and in August 2023, we reported data from the Phase 1 multiple-ascending dose (MAD) clinical trial of the prior DT-216 product candidate." https://www.sec.gov/Archives/edgar/data/1807120/000119312525266970/dsgn-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105062): "In December 2022, we reported positive initial data from the Phase 1 single-ascending dose (SAD) clinical trial and in August 2023, we reported data from the Phase 1 multiple-ascending dose (MAD) clinical trial of the prior DT-216 product candidate." https://www.sec.gov/Archives/edgar/data/1807120/000095017025105062/dsgn-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-065643): "In December 2022, we reported positive initial data from the Phase 1 single-ascending dose (SAD) clinical trial and in August 2023, we reported data from the Phase 1 multiple-ascending dose (MAD) clinical trial of the prior DT-216 product candidate." https://www.sec.gov/Archives/edgar/data/1807120/000095017025065643/dsgn-20250331.htm
- SEC Form 10-K (accession 0000950170-25-035910): "In December 2022, we reported positive initial data from the Phase 1 single-ascending dose (SAD) clinical trial and in August 2023, we reported data from the Phase 1 multiple-ascending dose (MAD) clinical trial of the prior DT-216 product candidate." https://www.sec.gov/Archives/edgar/data/1807120/000095017025035910/dsgn-20241231.htm
- SEC Form 10-K (accession 0000950170-25-035910): "In December 2022, we reported positive initial data from the Phase 1 SAD clinical trial and in August 2023, we reported data from the Phase 1 MAD clinical trial of the prior DT-216 product candidate." https://www.sec.gov/Archives/edgar/data/1807120/000095017025035910/dsgn-20241231.htm
- SEC Form 10-K (accession 0000950170-25-035910): "In December 2022, we reported positive initial data from the Phase 1 SAD clinical trial showing that DT-216 was generally well-tolerated and exhibited the ability to overcome the FXN transcription impairment that causes FA, with a greater than two-fold increase in FXN mRNA in the cohort with the highest response." https://www.sec.gov/Archives/edgar/data/1807120/000095017025035910/dsgn-20241231.htm

### Oct 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-10, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001193125-25-266970): "We withdrew our IND for the prior DT-216 product candidate in October 2023, and have initiated a Phase 1 SAD clinical trial in normal healthy volunteers in Australia to evaluate single doses using multiple routes of administration of DT-216P2, which uses the same drug substance, DT-216." https://www.sec.gov/Archives/edgar/data/1807120/000119312525266970/dsgn-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105062): "We withdrew our IND for the prior DT-216 product candidate in October 2023, and have initiated a Phase 1 SAD clinical trial in normal healthy volunteers in Australia to evaluate single doses using multiple routes of administration of DT-216P2, which uses the same drug substance, DT-216." https://www.sec.gov/Archives/edgar/data/1807120/000095017025105062/dsgn-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-065643): "We withdrew our IND for the prior DT-216 product candidate in October 2023, and have initiated a Phase 1 SAD clinical trial in normal healthy volunteers in Australia to evaluate single doses using multiple routes of administration of DT-216P2, which uses the same drug substance, DT-216." https://www.sec.gov/Archives/edgar/data/1807120/000095017025065643/dsgn-20250331.htm
- SEC Form 10-K (accession 0000950170-25-035910): "We withdrew our IND for the prior DT-216 product candidate in October 2023, and have initiated a Phase 1 SAD clinical trial in normal healthy volunteers in Australia to evaluate single doses using multiple routes of administration of DT-216P2, which uses the same drug substance, DT-216." https://www.sec.gov/Archives/edgar/data/1807120/000095017025035910/dsgn-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dt-216.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DT-216 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dt-216

```bibtex
@misc{secapidev_pdufa_dt_216_20261116,
  title        = {DT-216 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dt-216}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dt_216_20261116","title":"DT-216 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dt-216","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
